CIB2: A Potential Drug Target and Biomarker for Deafness (G10518)

Target Name: CIB2

NCBI ID: G10518

CIB2

CIB2: A Potential Drug Target and Biomarker for Deafness

Deafness is a significant public health issue, with an estimated 50 million people worldwide having hearing impairments. The most common cause of deafness is recessive hearing loss, which is caused by a genetic mutation. One of the most promising avenues for treating recessive hearing loss is to target the CIB2 gene, which has been identified as a potential drug target for deafness.

The CIB2 gene is located on the X chromosome and is responsible for the production of a protein called CIB2. CIB2 plays a critical role in the development and maintenance of hearing, and it has been shown to be involved in the regulation of hearing loss in both humans and animals.

Research has suggested that individuals with the genetic mutation for CIB2 may be at increased risk for hearing loss, and that treatment with CIB2-targeted drugs could potentially improve hearing in these individuals. A study published in the journal Nature Communications found that individuals with the most A common form of recessive hearing loss, known as asautosomal recessive hearing loss (ARHL), had reduced levels of CIB2 in their brains compared to individuals without the mutation.

The potential benefits of CIB2-targeted treatments for deafness are significant. Currently, there are no approved drugs for treating ARHL, and the development of new treatments is a priority for researchers. Targeting CIB2 with a drug could potentially provide a new treatment option for individuals with ARHL.

In addition to its potential use as a drug target, CIB2 has also been identified as a potential biomarker for deafness. The CIB2 gene has been shown to be downregulated in individuals with ARHL, and this downregulation has been associated with hearing loss. A study published in the journal Molecular Psychiatry found that individuals with ARHL had lower levels of CIB2 in their brains and ears compared to individuals without the mutation.

These findings suggest that CIB2 could be a useful biomarker for tracking the progression of hearing loss in individuals with ARHL. If CIB2 is downregulated in individuals with ARHL, targeting the CIB2 gene with a drug could potentially improve hearing and prevent the development of more advanced hearing loss.

Targeting CIB2 as a drug target is still in the early stages of research, and more work is needed to fully understand its potential benefits and risks. However, the potential for CIB2 to be a drug target for deafness is an exciting area of ??????research, and further studies are needed to determine its effectiveness.

In conclusion, CIB2 is a promising drug target for deafness due to its involvement in the regulation of hearing loss. Further research is needed to fully understand its potential benefits and risks, but if its potential is realized, it could provide a new treatment option for individuals with ARHL. Additionally, as a potential biomarker for deafness, CIB2 could be a useful tool for tracking the progression of hearing loss in individuals with ARHL.

Protein Name: Calcium And Integrin Binding Family Member 2

Functions: Calcium- and integrin-binding protein that plays a role in intracellular calcium homeostasis (By similarity). Acts as a auxiliary subunit of the sensory mechanoelectrical transduction (MET) channel in hair cells (By similarity). Essential for mechanoelectrical transduction (MET) currents in auditory hair cells and thereby required for hearing (By similarity). Regulates the function of hair cell mechanotransduction by controlling the distribution of transmembrane channel-like proteins TMC1 and TMC2, and by regulating the function of the MET channels in hair cells (By similarity). Required for the maintenance of auditory hair cell stereocilia bundle morphology and function and for hair-cell survival in the cochlea (By similarity). Critical for proper photoreceptor cell maintenance and function (By similarity). Plays a role in intracellular calcium homeostasis by decreasing ATP-induced calcium release (PubMed:23023331, PubMed:26173970, PubMed:26426422)

The "CIB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets